Envestnet Portfolio Solutions Inc. Trims Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Envestnet Portfolio Solutions Inc. decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,194 shares of the medical research company’s stock after selling 3,296 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Thermo Fisher Scientific were worth $21,430,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TMO. Avalon Trust Co boosted its stake in shares of Thermo Fisher Scientific by 6.2% during the 4th quarter. Avalon Trust Co now owns 36,784 shares of the medical research company’s stock worth $19,136,000 after acquiring an additional 2,162 shares in the last quarter. one8zero8 LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $3,405,000. Choate Investment Advisors increased its position in shares of Thermo Fisher Scientific by 6.0% in the fourth quarter. Choate Investment Advisors now owns 43,211 shares of the medical research company’s stock valued at $22,494,000 after buying an additional 2,462 shares in the last quarter. Diversified Enterprises LLC raised its stake in shares of Thermo Fisher Scientific by 6.6% during the 4th quarter. Diversified Enterprises LLC now owns 1,199 shares of the medical research company’s stock worth $624,000 after buying an additional 74 shares during the period. Finally, Frank Rimerman Advisors LLC grew its stake in Thermo Fisher Scientific by 3.0% in the 4th quarter. Frank Rimerman Advisors LLC now owns 4,821 shares of the medical research company’s stock valued at $2,508,000 after acquiring an additional 140 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on TMO shares. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price on the stock in a research report on Friday, January 10th. Raymond James reiterated an “outperform” rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. UBS Group raised their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Scotiabank lifted their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research note on Monday, February 3rd. Four research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $653.23.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This represents a 1.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $523.44 on Friday. The business’s fifty day simple moving average is $548.54 and its 200-day simple moving average is $559.17. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm has a market cap of $197.47 billion, a PE ratio of 31.67, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.33%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.41%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.